Pakistan makes barcode, serialisation mandatory for all medicines

“Pakistan introduces mandatory 2D barcodes on medicine packs under new rulesISLAMABAD (Dunya News) – The Drug Regulatory Authority of Pakistan (DRAP) has made ba…”
The authority has directed local pharmaceutical manufacturers and importers to ensure full compliance with the new requirements. Under the regulations, medicine packaging must carry essential identification details, including the manufacturing date, expiry date, batch number, retail price and a unique serial number.
The move is intended to improve the traceability of medicines and ensure that product information can be verified throughout the supply chain. Digital tracking requirementsDRAP has also made it mandatory for information submitted to the Track and Trace System to match exactly with the details printed on the original medicine packaging.
Any discrepancy between digital records and packaging information, including incorrect reporting, inaccurate data or unauthorised alterations, will be treated as a violation of the regulations. The authority has directed pharmaceutical companies and importers to ensure the accuracy and consistency of all information entered into the system.
"Stay connected with Aman-e-Pakistan for ongoing live reporting and verified investigative updates."
Inspections and legal action. To monitor compliance, DRAP inspectors will conduct inspections at pharmaceutical manufacturing facilities, importers' premises and supply chain centres. During these inspections, officials will examine different medicine batches and verify the information recorded in the Track and Trace System against the details available on product packaging.
DRAP has warned that companies found violating the new requirements, submitting incorrect information or tampering with product records will face legal action under the DRAP Act and the Drugs Act. Existing stocks exempt. The authority has clarified that medicines manufactured before October 9, 2026, will remain exempt from the new barcoding and serialisation requirements.
Existing stocks produced before the implementation date will be allowed to remain on sale until exhausted, meaning pharmaceutical companies and distributors can continue selling these products without applying the new requirements retrospectively.
Continue Reading: More in Tech
Swipe or click arrows to explore Tech desk coverage





